Video
Author(s):
Dr. Christopher Flowers showcases a comprehensive and updated analysis of the ROSEWOOD study, evaluating the efficacy and safety of combining zanubrutinib with obinutuzumab versus obinutuzumab monotherapy.
Venetoclax Plus PegC May Overcome Resistance to Prior BCL-2 Inhibitors in R/R AML
FDA Approval Insights: Obe-Cel in B-Cell Precursor ALL
Olverembatinib Demonstrates Efficacy and Safety in Heavily Pretreated CP-CML
Revisit the OncLive On Air Episodes From February 2024
FDA Approves Remestemcel-L for Pediatric Steroid-Refractory Acute Graft-vs-Host Disease
Orca-Q Leads to Low Rates of GVHD, Non-Relapse Mortality in High-Risk Hematologic Malignancies After Allo-HCT
Zongertinib Elicits Durable Responses in Pretreated Advanced HER2-Mutant NSCLC
Lenvatinib Shows Efficacy in Advanced HCC Post-Progression on Atezolizumab/Bevacizumab
Sacituzumab Govitecan Does Not Significantly Improve OS in Pretreated Urothelial Carcinoma
Active Monitoring Is Noninferior to Guideline Concordant Care in Low-Risk DCIS